Vivalis SA (VLS.PA)

VLS.PA

About

Vivalis SA is a France-based biopharmaceutical company that provides cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. The Company specializes in the field of embryonic stem (ES) cells and their use for... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.68
Market Cap (Mil.):	€122.74
Shares Outstanding (Mil.):	21.53
Dividend:	--
Yield (%):	--

Financials

	VLS.PA	Industry	Sector
P/E (TTM):	--	54.65	35.85
EPS (TTM):	-0.39	--	--
ROI:	-14.59	0.83	18.76
ROE:	-21.87	1.79	19.57

Latest News about VLS.PA

BRIEF-Intercell says proposed merger of equals with Vivalis

VIENNA, Dec 16 - Intercell AG : * Says proposed merger of equals between Vivalis and Intercell * Says Intercell shareholders to receive 13 Vivalis new ordinary shares for 40

16 Dec 2012

» More VLS.PA News

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Vivalis SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.